4.6 Article

How common is truly benign MS in a UK population?

Journal

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 90, Issue 5, Pages 522-528

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2018-318802

Keywords

-

Ask authors/readers for more resources

Objectives The prevalence and definition of benign multiple sclerosis (BMS) remain controversial. Most definitions are based on the Expanded Disability Status Scale (EDSS), not encompassing the wider impact of disease. The explanation for favourable outcomes remains unclear. We aim to provide a detailed characterisation of patients with low EDSS scores at long disease durations. Methods We screened a population-based registry containing 3062 people with MS to identify individuals with unlimited walking ability at disease durations >15 years. A representative cohort underwent detailed clinical assessment and classified as having BMS according to EDSS score <3, no significant fatigue, mood disturbance, cognitive impairment or disrupted employment, and had not received a disease-modifying therapy. We determined patient-reported perceptions of MS status and made comparisons with EDSS-based definitions. Results Of 1049 patients with disease duration of >15 years, 200 (19.1%) had most recent EDSS score <4.0. Detailed contemporary clinical assessment of a representative sample of 60 of these patients revealed 48 (80%) had an EDSS score of <4.0, 35 (58%) <3.0 and 16 (27%) <2.0. Only nine (15%) fulfilled our criteria for BMS; impaired cognition (57%) and effects on employment (52%) the most common causes for exclusion. Meanwhile, 33/60 (69%) patients considered their disease benign. Population frequency for BMS was estimated at 2.9% (95% CI 2.0 to 4.1). Conclusions Comprehensive assessment reveals a small minority of people with MS who appear genuinely benign after 15 years. Study of such individuals may uncover insights about disease pathogenesis. However, discrepancy between patient perception and clinician perception of BMS undermines use of the term 'benign' in clinical settings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Clinical Neurology

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

Massimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, Pietro Annovazzi, Paola Cavalla, Valentina Torri Clerici, Paolo Ragonese, Viviana Nociti, Marta Radaelli, Alice Laroni, Fabio Buttari, Lorena Lorefice, Diana Ferraro, Alberto Gajofatto, Luca Prosperini, Roberta Fantozzi, Laura Boffa, Roberta Lanzillo, Marcello Moccia, Marinella Clerico, Giovanna De Luca, Valentina Tomassini, Massimiliano Calabrese, Angela Borrelli, Damiano Paolicelli, Giorgia Teresa Maniscalco, Paola Gazzola, Antonio Gallo, Claudio Solaro, Eleonora Cocco, Claudio Gasperini, Carla Tortorella

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Article Clinical Neurology

Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register

Afagh Garjani, Rachael Hunter, Graham R. Law, Rodden M. Middleton, Katherine A. Tuite-Dalton, Ruth Dobson, David Ford, Stella Hughes, Owen R. Pearson, David Rog, Emma C. Tallantyre, Richard Nicholas, Richard Morriss, Nikos Evangelou, Roshan das Nair

Summary: The study found that during the first wave of the outbreak in the United Kingdom, people with MS were more likely to experience anxiety, depression, loneliness, worse social support, and worsened exercise habits compared to the general population.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

COVID-19 Vaccine Response in People with Multiple Sclerosis

Emma C. Tallantyre, Nicola Vickaryous, Valerie Anderson, Aliye Nazli Asardag, David Baker, Jonathan Bestwick, Kath Bramhall, Randy Chance, Nikos Evangelou, Katila George, Gavin Giovannoni, Andrew Godkin, Leanne Grant, Katharine E. Harding, Aimee Hibbert, Gillian Ingram, Meleri Jones, Angray S. Kang, Samantha Loveless, Stuart J. Moat, Neil P. Robertson, Klaus Schmierer, Martin J. Scurr, Sita Navin Shah, Jessica Simmons, Matthew Upcott, Mark Willis, Stephen Jolles, Ruth Dobson

Summary: The study found that some disease modifying therapies are associated with attenuated serological responses to SARS-CoV-2 vaccination in people with multiple sclerosis, including anti-CD20 monoclonal antibodies and fingolimod treatment. Additionally, vaccine type and treatment duration also impact vaccine response.

ANNALS OF NEUROLOGY (2022)

Editorial Material Endocrinology & Metabolism

Similarities and differences between multiple sclerosis and type 1 diabetes

Valeria Pozzilli, Eleonora Agata Grasso, Valentina Tomassini

Summary: Multiple sclerosis (MS) and type 1 diabetes (T1D) are chronic conditions stemming from immune system dysfunction, with differences in genetic susceptibility, age of onset, and treatment approaches.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2022)

Correction Clinical Neurology

Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Feb, 10.1007/s00415-022-11009-x, 2022)

Antonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, Giovanna De Luca, Valentina Tomassini, Paola Cavalla, Giorgia Teresa Maniscalco, Diana Ferraro, Viviana Nociti, Marta Radaelli, Maria Chiara Buscarinu, Damiano Paolicelli, Alberto Gajofatto, Pietro Annovazzi, Federica Pinardi, Massimiliano Di Filippo, Cinzia Cordioli, Emanuela Zappulo, Riccardo Scotto, Ivan Gentile, Antonio Luca Spiezia, Martina Petruzzo, Marcello De Angelis, Vincenzo Brescia Morra, Claudio Solaro, Claudio Gasperini, Eleonora Cocco, Marcello Moccia, Roberta Lanzillo

JOURNAL OF NEUROLOGY (2022)

Editorial Material Clinical Neurology

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk - No

Emma C. Tallantyre

MULTIPLE SCLEROSIS JOURNAL (2022)

Review Clinical Neurology

Decentralised clinical trials in multiple sclerosis research

Afagh Garjani, Brandon Jun-Yu Liu, Christopher Martin Allen, Douglas David Gunzler, Stephen William Gerry, Sarah Marie Planchon, Roshan das Nair, Jeremy Chataway, Emma C. Tallantyre, Daniel Ontaneda, Nikos Evangelou

Summary: Randomised controlled trials (RCTs) play a crucial role in MS research and decentralised clinical trials (DCTs) have emerged as a new approach, utilizing digital and mobile technologies for flexible and convenient participation. However, there are still gaps in knowledge regarding the design and conduct of DCTs in MS.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

Emma C. Tallantyre, Martin J. Scurr, Nicola Vickaryous, Aidan Richards, Valerie Anderson, David Baker, Randy Chance, Nikos Evangelou, Katila George, Gavin Giovannoni, Katharine E. Harding, Aimee Hibbert, Gillian Ingram, Stephen Jolles, Meleri Jones, Angray S. Kang, Samantha Loveless, Stuart J. Moat, Neil P. Robertson, Francesca Rios, Klaus Schmierer, Mark Willis, Andrew Godkin, Ruth Dobson

Summary: This study investigated the immune response of multiple sclerosis patients after receiving COVID-19 vaccines. The results showed that approximately one third of the patients seroconverted after receiving the third vaccine, indicating the benefit of boosters in this group. Nearly 80% of the patients had a measurable immune response after the third vaccine.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Endocrinology & Metabolism

Reduced brain oxygen metabolism in patients with multiple sclerosis: Evidence from dual-calibrated functional MRI

Hannah L. Chandler, Rachael C. Stickland, Eleonora Patitucci, Michael Germuska, Antonio M. Chiarelli, Catherine Foster, Shona Bhome-Dhaliwal, Thomas M. Lancaster, Neeraj Saxena, Sharmila Khot, Valentina Tomassini, Richard G. Wise

Summary: By using dual-calibrated functional magnetic resonance imaging (dc-fMRI), we found that cerebral blood flow, oxygen consumption, and oxygen diffusivity were significantly reduced in patients with multiple sclerosis (MS), while mitochondrial oxygen pressure was increased. These findings may indicate reduced oxygen demand or utilization in the MS brain and mitochondrial dysfunction.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2023)

Article Clinical Neurology

Contemporary study of multiple sclerosis disability in South East Wales

Katharine Elizabeth Harding, Gillian Ingram, Emma Clare Tallantyre, Fady Joseph, Mark Wardle, Trevor P. Pickersgill, Mark D. Willis, Valentina Tomassini, Owen Rhys Pearson, Neil P. Robertson

Summary: This study provides a detailed contemporary model of disability outcomes in a representative population-based MS cohort. The results support a trend of increasing time to disability milestones compared with historical reference populations, and document disability variation with the use of transitional matrices. This study has important implications for patient counseling, clinical trial design, and assessment of therapeutic interventions.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Multidisciplinary Sciences

Cerebrovascular reactivity in multiple sclerosis is restored with reduced inflammation during immunomodulation

Antonio Maria Chiarelli, Alessandro Villani, Daniele Mascali, Nikolaos Petsas, Emma Biondetti, Alessandra Caporale, Anna Digiovanni, Eleonora Agata Grasso, Paola Ajdinaj, Maria D'Apolito, Marianna Gabriella Rispoli, Stefano Sensi, Kevin Murphy, Carlo Pozzilli, Richard G. Wise, Valentina Tomassini

Summary: This study investigated the relationship between cerebrovascular reactivity (CVR) and neuroinflammation in patients with multiple sclerosis (MS). The findings showed lower CVR in patients before treatment compared to healthy controls and a negative correlation between pre-treatment CVR and grey matter volume. During treatment, CVR increased and was negatively correlated with pre-treatment CVR. Reduction in enhancing lesions was associated with increased CVR. The resolution of inflammation may restore altered cerebrovascular function in MS.

SCIENTIFIC REPORTS (2022)

Article Clinical Neurology

Relevance of Multiple Sclerosis Severity Genotype in Predicting Disease Course: A Real-World Cohort.

Karim L. Kreft, Emeka Uzochukwu, Sam Loveless, Mark Willis, Ray Wynford-Thomas, Katharine E. Harding, Peter Holmans, Michael Lawton, Emma C. Tallantyre, Neil P. Robertson

Summary: This study aimed to determine if the recent significant single-nucleotide variant (rs10191329A) and other genetic loci associated with overall disability outcomes in multiple sclerosis (MS) can influence individual patient management. The results showed no association between rs10191329A and various clinically relevant outcomes. However, two other suggestive SNVs (rs7289446G and rs868824C) were found to be associated with the development of fixed disability, and the HLA-DRB1*1501 locus was associated with age at onset.

ANNALS OF NEUROLOGY (2023)

Article Medicine, Research & Experimental

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial

Gogem Topcu, Laura Smith, Jacqueline R. Mhizha-Murira, Nia Goulden, Zoe Hoare, Avril Drummond, Deborah Fitzsimmons, Nikos Evangelou, Klaus Schmierer, Emma C. Tallantyre, Paul Leighton, Kimberley Allen-Philbey, Andrea Stennett, Paul Bradley, Clare Bale, James Turton, Roshan das Nair

Summary: This study aims to develop a cognitive screening and management pathway for people with multiple sclerosis (MS) and evaluate its feasibility. Through observational study, a feasibility randomized controlled trial, and semi-structured interviews, researchers will assess the clinical and cost-effectiveness of the intervention as well as its potential impact on the management of cognitive problems in MS patients.

PILOT AND FEASIBILITY STUDIES (2022)

Article Neuroimaging

A tractometry principal component analysis of white matter tract network structure and relationships with cognitive function in relapsing-remitting multiple sclerosis

Danka Jandric, Geoff J. M. Parker, Hamied Haroon, Valentina Tomassini, Nils Muhlert, Ilona Lipp

Summary: Understanding the brain changes underlying cognitive dysfunction in multiple sclerosis (MS) is crucial for improving monitoring and treatment. This study explored the relationship between changes in white matter and cognitive symptoms, using a tractometry approach. The findings revealed a main covariance pattern that explained the most variance in microstructure across all white matter tracts. This covariance pattern contributed to explaining a moderate degree of variance in one cognitive domain in MS. These findings emphasize the importance of investigating the relationship between normal appearing white matter and cognitive impairment in MS.

NEUROIMAGE-CLINICAL (2022)

No Data Available